A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Clinical trial NCT05387616 · UNKNOWN
Trial details
- NCT number
- NCT05387616
- Sponsor
- Ludwig-Maximilians - University of Munich
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-19
- Primary completion
- 2023-09-16
- Enrollment
- 98
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.